医学
布拉迪酵母菌
幽门螺杆菌
内科学
需要治疗的数量
不利影响
相对风险
安慰剂
随机对照试验
置信区间
养生
胃肠病学
子群分析
阿莫西林
荟萃分析
辅助
意向治疗分析
临床试验
质子抑制剂泵
抗生素
作者
Hong Kai Chang,Lu Bo Shi,Hui Xin Song,Peng Li
标识
DOI:10.1111/1751-2980.70071
摘要
OBJECTIVE: To systematically evaluate the efficacy, safety, and optimal administration parameters (dosage, treatment duration, regimen type, and publication era of the articles) of Saccharomyces boulardii as an adjunct therapy to Helicobacter pylori eradication therapy. METHODS: We searched PubMed, Web of Science, and EMBASE databases for randomized controlled trials (RCTs) comparing S. boulardii and placebo in addition to H. pylori eradication that were published up to January 2026. Pooled risk ratio (RR) and the corresponding 95% confidence interval (CI), absolute risk differences (ARD), and numbers needed to treat (NNT) were calculated. Certainty of evidence was assessed using GRADE. RESULTS: Nineteen RCTs were included for analysis. Adjuvant S. boulardii significantly improved H. pylori eradication in adults (n = 15; RR 1.07, 95% CI 1.03-1.10; ARD +5.7%; NNT 18) and children (n = 3; RR 1.12, 95% CI 1.03-1.23; ARD +9.8%; NNT 10). Eradication gain was significant with triple therapy (n = 12; RR 1.08, 95% CI 1.03-1.14). Eradication efficacy was consistent across different dosages, treatment durations, and publication eras (p > 0.05 for subgroup interactions). Furthermore, S. boulardii significantly halved overall adverse events (n = 11; 19.7% vs. 36.0%; RR 0.51, 95% CI 0.39-0.66; NNT 6). GRADE certainty was moderate for eradication and low for adverse events. CONCLUSIONS: CFU/day for 10-14 days appears to be a reasonable and pragmatic regimen. SYSTEMATIC REVIEW REGISTRATION: PROSPERO registration no. CRD420251271815.
科研通智能强力驱动
Strongly Powered by AbleSci AI